| Phase 3 |
| NCT05303519 |
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) |
Glioma |
Recruiting |
2026-07-01 |
| NCT07154706 |
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC… |
Non-small Cell Lung Cancer (NSCLC) |
Recruiting |
2026-05-19 |
| NCT06564324 |
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally… |
Non Small Cell Lung Cancer |
Recruiting |
2026-04-13 |
| NCT07712757 |
Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma |
Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation |
Not Yet Recruiting |
2026-07-17 |
| Phase 2 |
| NCT07703436 |
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who… |
Grade 2 IDH1-mutant Glioma |
Not Yet Recruiting |
2026-08-27 |
| NCT04395677 |
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene |
Non Small Cell Lung Cancer |
Active, Not Recruiting |
2026-02-06 |
| NCT04919811 |
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC |
Non Small Cell Lung Cancer |
Active, Not Recruiting |
2026-01-07 |
| Phase 1/2 |
| NCT06334432 |
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors |
Advanced Solid Tumor |
Active, Not Recruiting |
2026-01-14 |
| Phase 1 |
| NCT07742384 |
Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib |
Healthy Adult Participants |
Not Yet Recruiting |
2026-08-03 |